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Abstract
Based on a set of subjects and a collection of attributes obtained from the Alzheimer’s Dis-
ease Neuroimaging Initiative database, we used redescription mining to find interpretable
rules revealing associations between those determinants that provide insights about the Alz-
heimer’s disease (AD). We extended the CLUS-RM redescription mining algorithm to a con-
straint-based redescription mining (CBRM) setting, which enables several modes of
targeted exploration of specific, user-constrained associations. Redescription mining
enabled finding specific constructs of clinical and biological attributes that describe many
groups of subjects of different size, homogeneity and levels of cognitive impairment. We
confirmed some previously known findings. However, in some instances, as with the attri-
butes: testosterone, ciliary neurotrophic factor, brain natriuretic peptide, Fas ligand, the
imaging attribute Spatial Pattern of Abnormalities for Recognition of Early AD, as well as the
levels of leptin and angiopoietin-2 in plasma, we corroborated previously debatable findings
or provided additional information about these variables and their association with AD patho-
genesis. Moreover, applying redescription mining on ADNI data resulted with the discovery
of one largely unknown attribute: the Pregnancy-Associated Protein-A (PAPP-A), which we
found highly associated with cognitive impairment in AD. Statistically significant correlations
(p 0.01) were found between PAPP-A and clinical tests: Alzheimer’s Disease Assessment
Scale, Clinical Dementia Rating Sum of Boxes, Mini Mental State Examination, etc. The
high importance of this finding lies in the fact that PAPP-A is a metalloproteinase, known to
cleave insulin-like growth factor binding proteins. Since it also shares similar substrates with
A Disintegrin and the Metalloproteinase family of enzymes that act as α-secretase to physio-
logically cleave amyloid precursor protein (APP) in the non-amyloidogenic pathway, it could
be directly involved in the metabolism of APP very early during the disease course. There-
fore, further studies should investigate the role of PAPP-A in the development of AD more
thoroughly.
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Introduction
Alzheimer’s Disease (AD) is an irreversible neurodegenerative disease that results in progres-
sive deterioration of cognitive abilities and behavioural control due to synapse and neuron
loss. It is the most common cause of dementia among older adults. Although available medica-
tions for treatment of mild to moderate AD (donepezil, galantamine, and rivastigmine) and
severe AD (memantine) help to some level, these drugs do not modify the underlying disease
process.
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) [1] aims to collect various imag-
ing and biomarker data, that could be potentially useful in diagnostics and treatment of AD.
The analysis of these data provides means to potentially extend our understanding of the dis-
ease, its impact on various functions of human comportment and cognitive functions, and
tracking its progression.
In this work, we analysed the data obtained from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database [1], containing clinical and biological measurements (listed in S1–
S3 Files and available at http://adni.loni.usc.edu/). These measurements are taken for a set of
subjects in order to test for presence of AD and the level of subjects’ cognitive impairment. We
divided the attributes in two main groups: clinical (clin) and biological (bio).
Clinical attributes have been obtained from numerous questionnaires and neuropsycholog-
ical instruments designed to test cognition and memory with the hope of early detection of
AD. These tests have been carefully designed, studied and regularly updated to increase the
detection of various forms of cognitive impairment. Many such tests exist [2], but there has
been no unique measure that can be used to reliably make the diagnosis [3]. Thus, combining
different tests has been shown to provide more reliable results. Biological attributes have con-
tained neuroimaging data of a number of methods to visualize brain activity, such as MRI and
PET scans, along with some related and derived scores. They have also contained biospeci-
mens: a number of blood tests and measurements, and information about the subjects’ genetic
markers (genetic data). These attributes have been generally considered less reliable, but are
still actively investigated with the aim to aid in the early detection of AD and to help under-
stand its complex genetic, epigenetic, and environmental landscapes.
Manual investigation of associations between attributes and analysis of their effects would
require insurmountable efforts, which prompted us to use a data mining technique called rede-
scription mining.
Work related to understanding cognitive impairment
Considerable work has been oriented towards understanding the role of biological or clinical
attributes, determining correlations between different attributes and assessing their predictive
power for determining the level of cognitive impairment.
Researchers have used neural imaging (MRI, PET, etc.) [4–6] to predict levels of cognitive
impairment. For example, Doraiswamy et al. [7] studied PET images of subjects with cognitive
decline. Donovan et al. [8] studied correlations between regional cortical thinning and worsen-
ing of apathy and hallucinations. Guo et al. [9] studied the effects of intracranial volume on
association between clinical disease progression and brain atrophy or apolipoprotein E geno-
type. Hostage et al. [10] studied the effects of apolipoprotein E (APOE alleles) ε4 and ε2 on
hippocampal volume. Other investigators have also studied the role of apolipoprotein E [11] in
early mild cognitive impairment. These are just a few samples of the huge set of studies of cor-
relations between biological, clinical attributes and the level of cognitive impairment. More
extensive list can be found at http://adni.loni.usc.edu/news-publications/publications/.
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Recently, Gamberger et al. used a multi-layer clustering method [12] to identify clusters of
AD patients with respect to several clinical and biological attributes [3]. The same method was
applied [13] to detect differences between clusters containing male and female patients. Bresk-
var et al. used Predictive Clustering Trees (PCTs) [14] to discover and analyse patient clusters.
They focused on relations between biological features and the progression of AD by observing
behavioural response of patients and their study partners (persons who are in frequent contact
with the patient, study with the patient, and are able to assess the patient’s functioning in daily
life).
Redescription mining and related fields
In this section, we provide background information related to redescription mining and moti-
vate its choice as a data mining technique used in our work.
The most open-ended, unsupervised data-mining technique, clustering [15–19] finds and
groups similar instances based on a predefined similarity measure. It is used when underlying
and possibly interesting natural grouping is unavailable, but also to reveal new groups that
were previously unknown. Clustering techniques typically do not create interpretable models
of data, so one has to apply other technique in order to get interpretable descriptions of
induced clustering. One such approach, limited to using a single attribute set, is conceptual
clustering [20, 21] that aims at finding clusters that can be described with concepts derived by
using some description language.
There exists a broad group of descriptive pattern mining techniques that find and describe
subsets of examples using single attribute set or view.
For example, association rule mining [22] finds associations between items (in transaction
databases) or different attributes in the form of unidirectional rules. Interesting associations
are typically selected based on support and confidence scores of association rules and possibly
some other interestingness measures.
Subgroup discovery [23, 24] is a technique that finds queries describing groups of instances
having unusual and interesting statistical properties with respect to the target variable. Con-
trast Set Mining [25] identifies monotone conjunctive queries that best discriminate between
instances containing one target class from all other instances (e.g. subjects with diagnosis Alz-
heimer’s Disease (AD) vs Control (CN) subjects).
In contrast to techniques operating on a single set of attributes, multi-view techniques offer
advantages when the available data contains information from various sources or descriptions
of different properties of instances (as is the case in this study).
Two-view data association discovery [26] aims at finding a small, non—redundant set of
associations that provide insight in how two views are related. The approach can create both
bidirectional and unidirectional rules as translation patterns.
Redescription mining, introduced by Ramakrishnan et al. [27], is capable of mining
descriptions of subsets of data described by multiple sets of attributes. The building blocks of
redescriptions are called queries (logical formulas describing a set of instances by using attri-
butes from some particular view). Redescription queries can describe the same or very similar
subset of instances with different queries, which is an important capability in the context of
knowledge discovery.
Rationale for using redescription mining
Redescription mining offers advantages over related techniques and provides specific results
required for our analysis. The multi-view and descriptive capabilities of redescription mining
make it suitable for relating different biological attributes, many with unknown or scarcely
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explored role and effects on cognitive impairment, to clinical attributes designed to detect cog-
nitive impairment and make the preliminary diagnosis.
Although a two-view data association discovery approach can be applied to this data, we
aimed at discovering interesting equivalence-like associations between biological and clinical
attributes on different support levels and validating them with the subjects diagnosis, that is
possible with redescription mining. Two-view association discovery is also somewhat limited
as it is designed to mine Boolean data and to provide small and non-redundant sets of associa-
tions (translations) between different attribute sets. In our discovery study we aim to create,
potentially larger number, of understandable redescriptions that would be used as a basis for
the thorough statistical analyses and the analysis performed by the domain expert.
Similar data and attributes, related to AD, have been studied before [3, 13, 14, 28]. However,
this study is focussed on the analysis of the ADNI data using redescription mining, which
enables using its specific advantages over other approaches to find potentially new insights and
improve our understanding of the genesis of AD.
Materials and methods
This section contains descriptions of data, notation and related redescription mining
approaches, CLUS-RM algorithm [29, 30] and the motivation for its use in this work. It
includes description of algorithmic extensions incorporated into CLUS-RM that enable fully
automated constraint-based redescription mining, where we generalize the attribute and
instance level constraints introduced by Zaki and Ramakrishnan [31].
Data description
For this study, we extracted data from the ADNI database [1]. To obtain the data, we used the
Merged ADNI 1/GO/2 Packages for R [32] located in study info section of the download data
page in the database. This package contains majority of available datasets in the format of R
data frames. The basis of our datasets was contained in the adnimerge data table, which con-
tains measurement of several clinical attributes (derived by using questionnaires, observations
by doctors and other tests measuring level of cognition) and biological attributes (different
blood tests, genetic markers, attributes derived from brain images, volumes of different parts
of the brain etc.) for 1,737 subjects. There was also a target variable—diagnosis (not used for
redescription construction) containing categorical values: control normal (CN), significant
memory concern (SMC), early mild cognitive impairment (EMCI), late mild cognitive
impairment (LMCI) and probable AD. Values of a target variable can be considered as ordered
(levels of cognitive impairment). Each subject was assigned in exactly one category and there
were no missing values for this variable. By examining the subjects contained in the adnimerge
data table, we have noticed two distinct groups of subjects for whom some additional distinct
attributes were measured. Therefore, we created and studied three related datasets.
The distributions of patients, divided by the level of cognitive impairment, for all three
datasets are provided in Table 1.
Division of attributes to clinical (clin) and biological (bio) forms two disjoint sets of attri-
butes used as views in redescription mining. In all datasets, subjects or patients constitute the
instances for the redescription mining process.
Table 2 contains full names and abbreviations for all attributes required to present our
work, while Tables 3 and 4 contain corresponding basic statistical information for these attri-
butes. Due to data normalization (especially of biological attributes), the original measuring
units do not correspond to the attribute values and are not specified in the tables.
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The first dataset (D1) contained 1,737 subjects. The dataset contained a number of biologi-
cal attributes such as APOE genotype, different brain measurements, such as the volume of the
whole brain, the hippocampus, ventricles, and many other structures, including brain images
obtained by using the 18fluorodeoxyglucose (FDG)-PET method. The dataset contained vari-
ous blood analysis, such as levels of white and red blood cells, protein (RCT12) and glucose
(RCT11) levels, and many others. It also contained a number of neuropsychological tests, such
as the Alzheimer Disease Assessment Scale (ADAS11, ADAS13, etc.), several different Rey
Auditory Verbal Learning Tests (RAVLT), Mini-Mental State Examination (MMSE), Func-
tional Assessment Questionnaire (FAQ), and others, including several attributes related to
clinical dementia rating (CDR) and geriatric depression scale (GDS). Several features describ-
ing the subject’s symptoms, such as presence of nausea (BCNAUSEA), vomiting (BCVOMIT),
Table 1. The number of subjects contained in datasets D1, D2 and D3 divided by the level of cognitive impairment.
Dataset Total CN SMC EMCI LMCI AD
D1 1737 417 106 310 562 342
D2 918 188 106 310 164 150
D3 820 229 0 1 398 193
https://doi.org/10.1371/journal.pone.0187364.t001
Table 2. A list of clinical and biological attributes discussed in the text.
Attribute (bio) Full name Attribute (bio) Full name
Aβ1−40 Plasma biomarker Aβ1−40 ICV Intracranial volume
Aβ1−42 Plasma biomarker Aβ1−42 Insulin Insulin
ANG2 Angiopoietin-2 Leptin Leptin
APAII Apolipoprotein A-II MCRPHMIF Macrophage migration inhibitory factor
APOB Apolipoprotein B PAPP-A Pregnancy associated plasma protein A/ pappalysin-1
APOE ε4 Gene APOE ε4 PLMNRARC Pulmonary and activation-regulated chemo
AV45 18F-florbetapir PPP Pancreatic polypeptide
BAT126 Level of vitamin B12 PTAU Phospho-tau protein
BNP Brain natriuretic peptide RCT11 Serum glucose
CKMB Creatine kinase level RCT12 Total protein
CNTF Ciliary neurotrophic factor RCT14 Creatine kinase
Entorhinal Entorhinal cortex volume SPARE_AD Spatial Pattern of Abnormalities for Recognition of Early AD
FASL Fas ligand T2TCV T2 weighted total intracranial volume
FDG-PET 18fluorodeoxyglucose—positron emission tomography TAU Tau protein
Fusiform Volume of the fusiform gyrus TNC Tenascin-C
Hippocampus Hippocampus volume TSTSTRNT Total blood testosterone
HMT8 Neutrophils Ventricles Volume of the lateral ventricles
HMT18 Eosinophils WholeBrain Whole brain volume
Attribute (clin) Full name Attribute (clin) Full name
ADAS11 11-item ADAS test score CDRSB Clinical Dementia Rating Sum of Boxes
ADAS13 13-item ADAS test score EcogPtPlan Participant everyday cognition planning
BCNAUSEA Presence of nausea FAQ Functional Assessment Questionnaire
BCSWEATN Presence of sweating MMSE Mini-Mental State Examination
BCVOMIT Presence of vomiting MOCA Montreal Cognitive Assessment
CDGLOBAL Global cognitive dementia rating Q13SCORE Question 13 from the ADAS test
CDJUDGE Judgement and problem solving score RAVLT Rey Auditory Verbal Learning Test immediate
CDMEMORY Memory score
https://doi.org/10.1371/journal.pone.0187364.t002
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sweating (BCSWEATN), as well as results of various neurological examinations were also
included. Information about attributes and subjects contained in D1 are available in S1 File.
The second dataset (D2) contained 918 subjects. In addition to features contained in the
first dataset, it also contained features describing subjects’ performance on Montreal Cognitive
Assessment (MOCA) scale and features related to the Eastern Cooperative Oncology Group
(ECOG) Scale of Performance Status. It also contained values of cerebrospinal fluid (CSF),
total tau (TAU) and phospho-tau (PTAU) levels. Information about attributes and subjects
contained in D2 are available in S2 File.
Table 3. Information about value range and percentage of missing values for biological attributes discussed in the text. Absence of an attribute from
a dataset is denoted with “-” in the range and missing columns.
Attribute D1 D2 D3
Range Missing Range Missing Range Missing
APOE ε4 {0, 1, 2} 1% {0, 1, 2} 2% {0, 1, 2} 0%
BAT126 [96, 6725] 12% [96, 6725] 15% [99, 3429] 8%
Entorhinal [1426, 5896] 16% [1438, 5896] 13% [1426, 5731] 39%
Fusiform [8991, 29950] 16% [10012, 29950] 13% [8991, 24788] 39%
Hippocampus [2991, 10769] 14% [2991, 10602] 10% [3091, 10769] 19%
HMT8 [0.98, 11.64] 12% [1.22, 10.22] 15% [0.98, 11.64] 7%
HMT18 [0,35.8] 12% [0, 24] 15% [0,34.8] 7%
ICV [1.1, 2.1]  106 1% [1.1, 2.1]  106 2% [1.1, 2.1]  106 0%
RCT11 [55, 413] 11% [61, 315] 15% [55, 413] 6%
RCT12 [5.7,9.7] 11% [5.9,8.4] 15% [5.7,9.7] 6%
RCT14 [18, 2658] 11% [23, 2658] 15% [18, 721] 6%
Ventricles [0.6, 1.5]  105 5% [0.6, 1.3]  105 7% [0.6, 1.5]  105 2%
WholeBrain [0.7, 1.5]  107 3% [0.8, 1.5]  107 4% [0.7, 1.4]  107 1%
AV45 [0.84, 2.03] 49% [0.84, 2.03] 3% - -
FDG-PET [3.49,8.54] 25% [3.49,8.54] 2% - -
PTAU - - [9.4, 173.3] 58% - -
Aβ1−40 - - - - [13.0,371.8] 13%
Aβ1−42 - - - - [4.6, 102.8] 12%
ANG2 - - - - [0.11, 1.46] 31%
APOAII - - - - [2.35,3.18] 31%
APOB - - - - [2.89,3.47] 31%
BNP - - - - [1.86,4.13] 31%
CKMB - - - - [−1.43,0.59] 31%
CNTF - - - - [0.88,3.48] 31%
FASL - - - - [0.85,3.62] 31%
Insulin - - - - [−0.68, 1.43] 31%
Leptin - - - - [−0.82, 2.0] 31%
MCRPHMIF - - - - [−1.2,0.8] 31%
PAPP-A - - - - [−2.34, −0.85] 31%
PLMNRARC - - - - [1.6, 2.7] 31%
PPP - - - - [−0.004,3.16] 31%
SPARE_AD - - - - [−3.86, 2.79] 0%
T2TCV - - - - [1003, 1922] 1%
TAU - - - - [19.9,300.5] 58%
TNC - - - - [1.9,3.5] 31%
TSTSTRNT - - - - [−1.44, 1.52] 31%
https://doi.org/10.1371/journal.pone.0187364.t003
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The third dataset (D3) contained 820 subjects. It was extremely useful to study the differ-
ences and special properties of healthy subjects as compared to patients with severe stages of
dementia. This dataset lacked information about ECOG Scale of Performance Status, MOCA,
and information about CSF biomarkers, but it contained several additional attributes related
to hormones and proteins measured. It also contained information about T2 weighted total
cranial vault segmentation (T2TCV) and plasma biomarkers Aβ1−40 and Aβ1−42. One particu-
larly useful imaging attribute was Spatial Pattern of Abnormalities for recognition of early AD
(SPARE_AD), which was specifically constructed to help in early detection of AD. Dataset D3
also contained the attribute PAPP-A which is analysed in more detail in this work. The AD
assessment scale contained many additional attributes corresponding to different cognitive
tasks, the full set of attributes being publicly available on the ADNI web page http://adni.loni.
usc.edu/. Information about attributes and subjects contained in D3 are available in S3 File.
Table 4. Information about value range and percentage of missing values for clinical attributes discussed in the text. Absence of an attribute from a
dataset is denoted with “-” in the range and missing columns. If some dataset has equal range as D1, this is denoted with “-||-” in the appropriate field.
Attribute D1 D2 D3
Range Missing Range Missing Range Missing
ADAS11 [0,42.67] 0% [0, 40] 0% [0, 40] 0%
ADAS13 [0,54.67] 1% [0, 52] 1% [0, 52] 1%
BCNAUSEA {0, 1} 0% -||- 0% -||- 0%
BCSWEATN {0, 1} 0% -||- 0% -||- 0%
BCVOMIT {0, 1} 0% -||- 0% -||- 0%
CDGLOBAL {0, 0.5, . . .2} 0% -||- 0% {0, 0.5, 1} 0%
CDJUDGE {0, 0.5, . . ., 3} 0% -||- 0% -||- 0%
CDMEMORY {0, 0.5, . . ., 3} 0% -||- 0% {0, . . ., 2} 0%
CDRSB {0, 0.5, . . ., 10} 0% -||- 0% {0, . . ., 9} 0%
FAQ {0, 1, . . ., 30} 1% {0, 1, . . ., 28} 1% -||- 0%
MMSE {18, 19, . . ., 30} 0% {19, . . ., 30} 0% -||- 0%
Q13SCORE {0, 0.5, . . ., 10} 1% -||- 0% -||- 1%
RAVLT {0, 1, . . ., 71} 0% {1, . . ., 71} 0% {0, . . ., 69} 0%
EcogPtPlan - - [1, 4] 1% - -
MOCA - - {4, 5, . . ., 30} 1% - -
https://doi.org/10.1371/journal.pone.0187364.t004
Fig 1. Relations between attributes used in constructed datasets D1, D2 and D3. Left Venn diagram depicts
clinical and right Venn diagram biological attributes.
https://doi.org/10.1371/journal.pone.0187364.g001
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Relation between attributes used in different datasets is visible in Fig 1.
Division among subjects in the constructed datasets is as follows: D1 = D2 [ D3, D2 \ D3 =
{2002}, where 2002 denotes the roster id (RID), unique id of subject contained in the
intersection.
In all analysed datasets, there were slightly more males than females. Males constitute 55%
of the first, 52% of the second and 58% of the third dataset. They also constitute 57%, 53% and
61% of all subjects with some level of cognitive impairment in these datasets. Pregnancy in
female subjects can alter levels of PAPP-A attribute. Although the information about the preg-
nancy status for female subjects analysed was not directly available in our dataset, documents
describing ADNI1 exclusion criteria (which cover patients contained in our dataset D3) [33]
clearly state that female participants must be sterile or two years past childbearing potential to
be included in the study group. Documents related to ADNIGO [34] and ADNI2 exclusion
criteria [35] state that the participant must not be pregnant, lactating or of childbearing poten-
tial. As a result of these exclusion criteria, we can assume that the PAPP-A levels, for the stud-
ied female subjects, were not influenced by pregnancy.
Redescription mining
Redescription mining [27] works on a dataset D, containing |D| instances and one set, or two
disjoint sets of attributes (views, denoted as W1 and W2) describing these instances. A rede-
scription (as for example R = (q1, q2)) is a pair of queries, containing one query per view. Each
query is a propositional logic formula that can contain conjunction, disjunction or negation
operators and is used to define conditions on values of a subset of attributes from a particular
view. The subset of instances described by a query qi, denoted supp(qi) is called the query sup-
port set. The support set of a redescription is the set of instances described by both queries that
constitute this redescription: supp(R) = supp(q1) \ supp(q2). We also use the notation E1,1 to
denote the set of instances described by both queries, E1,0 a set of instances described by the
first query but not described by the second query, E0,1 a set of instances described by the sec-
ond query but not described by the first query, E0,0 a set of instances that are not described by
either query. E?,1 denotes a set of instances for which it is not possible to determine if they are
described by the first query, due to missing values, but are described by the second query, E1,?
contains a set of instances described by the first query but for which it is not possible to deter-
mine if they are described by the second query, due to missing values, E?,0 denotes a set of
instances for which it is not possible to determine if they are described by the first query, due
to missing values, and are not described by the second query, E0,? contains a set of instances
not described by the first query but for which it is not possible to determine if they are
described by the second query, due to missing values. The set E?,? contains instances for which
it is not possible to determine if they are described by either query due to missing values. attr
(R) denotes a multiset of attributes contained in redescription queries, whereas attrs(R) repre-
sents a corresponding set of attributes. attr(D) denotes all attributes contained in both views of
the dataset and R denotes a redescription set.
We evaluate the quality of mined redescriptions by using two measures [36]: i) the Jaccard
index, which measures the similarity of support sets of the two redescription queries (also
often called accuracy of redescription, since it measures how close two query support sets are
to containing identical set of instances) and ii) statistical significance of the observed rede-
scription, expressed through a p-value.
The Jaccard index is defined as:
JðRÞ ¼
jsuppðq1Þ \ suppðq2Þj
jsuppðq1Þ [ suppðq2Þj
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Assessment of the statistical significance of the redescription R = (q1, q2) is based on an
assumption that the support sets, of two queries q1 and q2, are selected randomly, with mar-
ginal probabilities p1 ¼
jsuppðq1Þj
jDj and p2 ¼
jsuppðq2Þj
jDj respectively. The statistical significance of rede-
scription measures how probable it is to obtain overlap of the size |supp(R)| or larger when
sampling two subsets of instances from a set of size |D|, using sampling probabilities p1 and p2
respectively. The size of the intersection follows a binomial distribution and the probability we
are looking for can hence be written as:
pVðRÞ ¼
XjDj
n¼jsuppðRÞj
jDj
n
 
ðp1  p2Þ
n
 ð1   p1  p2Þ
jDj  n
Example 1. Redescription Rex = (qclin, qbio), discovered on dataset D3, whose queries are
defined as: qclin: 0.0 GDTOTAL 2.0 ^ GDALIVE = 0.0 ^ CDMEMORY = 0.0 qbio: 0.5
HMT18 16.0 ^ −3.86 SPARE_AD −0.93, provides alternative descriptions of 156 differ-
ent normal control subjects. Query qclin describes 204 subjects with specific value for the fol-
lowing clinical attributes: memory score (CDMEMORY), total score in geriatric depression
scale (GDTOTAL), score on a question Do you think its wonderful to be alive now? (GDALIVE)
while query qbio describes 172 subjects having specific values for biological attributes such as
percentage of Eosinophils (HMT18) and a Spatial Pattern of Abnormalities for Recognition of
Early Alzheimer’s disease (SPARE_AD). The set of subjects described by at least one query of
redescription Rex contains 220 subjects, i.e |supp(qclin) [ supp(qbio)| = 220. For 156 of 220 sub-
jects, both queries are valid, i.e. |supp(qclin) \ supp(qbio)| = 156. This means that the Jaccard
index (accuracy) for this redescription is 156
220
¼ 0:709. The redescription is statistically signifi-
cant with the p-value< 2  10−17 (which can be computed by using the formula above). It
means that it is highly unlikely to observe a redescription of support size 156 or larger given
that we combine two statistically independent queries, with marginal probabilities p1 ¼ 204820 ¼
0:25 and p2 ¼ 172820 ¼ 0:21, into a redescription Rex.
Existing approaches for redescription mining. The first algorithm for redescription
mining, called CARTwheels, was developed by Ramakrishnan et al. [27]. Several redescription
mining algorithms have been developed since, all of which can handle Boolean attributes.
From these, some algorithms [29, 30, 37, 38] work also with categorical and numerical attri-
butes. Currently, only two redescription mining algorithms ReReMi [37] and CLUS-RM [29,
30], work with attributes containing missing values.
Redescription mining algorithms can be divided into three main categories: a) algorithms
based on itemset mining, b) greedy algorithms and c) tree-based algorithms.
Itemset mining based redescription mining algorithms utilize different itemset mining
methods to create itemsets, which are used to create redescriptions. Approach by Zaki and
Ramakrishnan [31] and the approach by Parida and Ramakrishnan [39], use a lattice (partially
ordered set) of attribute sets to find redescriptions. Approach developed by Gallo et al. [40] is
based on frequent itemset mining. The field is known as Frequent Itemset Mining, because the
notion of frequency (support size, the apriori principle) is central in obtaining practical
algorithms.
Greedy algorithms for redescription mining work by incrementally updating queries with
the goal of increasing redescription accuracy. The first algorithm developed in this category was
the greedy algorithm from Gallo et al. [40]. This algorithm has been extended by Galbrun and
Miettinen [37], under the name ReReMi, to work with categorical and numerical attributes.
Tree-based algorithms use decision trees [41] or Predictive Clustering trees (PCTs) [42] to
create redescriptions. This category includes the first developed algorithm for redescription
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mining called CARTwheels, developed by Ramakrishnan et al. [27]. This algorithm works by
building two decision trees per iteration (one for each view) that are joined in the leaves. Rede-
scriptions are created by reading off the conditions along the paths from the root node of the
first tree to some specified class (which constitutes one redescription query) and the paths
from the root node to the matching leafs of the second tree (which constitutes the second rede-
scription query). All created trees are of the same predefined depth, and the process iterates for
a predefined number of iterations. This algorithm uses multiclass classification to guide the
search between the two views. Layered trees (LayeredT) and Split trees (SplitT) algorithms
developed by Zinchenko [38] use a different methodology of decision tree construction to
obtain redescriptions. Instead of creating fully grown trees of predefined depth, the Layered
trees algorithm creates one or more depth one trees at each algorithm step. For each leaf of the
tree under construction, at some fixed iteration, the Layered trees algorithm builds a new
depth one tree and appends it to the corresponding leaf of the existing tree (thus increasing its
complexity and size). The algorithm allows creating more informed splits, since at a certain
step of tree construction, the algorithm uses information about splits created at a correspond-
ing level of the tree constructed on the opposite view. To construct a tree of maximal depth,
the algorithm considers all nodes of the tree created on the opposite view (not just the leaves of
a fully grown tree as in CARTwheels). The Split trees algorithm creates decision trees of
increasing size. At each step of tree construction, the depth is increased by one and a whole
new tree of larger depth is built (completely replacing the previously constructed tree) until
trees of maximally allowed depth are built. This algorithm simultaneously refines classes (since
it obtains finer splits with trees of larger depth) and trees (by increasing their complexity and
providing more specific classes).
The CLUS-RM algorithm developed by Mihelcic et al. [29, 30] uses multi-target Predictive
Clustering trees (PCTs) [42, 43], instead of decision trees to construct redescriptions. Using
multi-target PCTs allows using information about all nodes (intermediate nodes as well as
leaves) in the constructed PCT simultaneously to create redescriptions (which increases accu-
racy, diversity and number of produced redescriptions). This algorithm has been extended by
Mihelcic et al. [44] to use a random forest of PCTs which further increases accuracy and diver-
sity of produced redescriptions. The CLUS-RM is also equipped with a redescription set con-
struction procedure called redescription set optimization [29, 30, 44]. It enables incorporating
quality constraints in multi-objective optimization manner and uses all produced redescrip-
tions to create a reduced redescription set of user-defined size. A generalized version of rede-
scription set optimization has been presented by Mihelcic et al. [45]. In addition to its main
purpose of redescription set construction, this procedure allows for use of ensembles of rede-
scription mining algorithms, influencing the structure of produced sets through user-defined
importance weights and performing computationally efficient construction of multiple rede-
scription sets with different properties, which is beneficial for exploration [45].
Choice of methodology, redescription accuracy measure
and a query language
In this section, we describe our motivation underlying the use of CLUS-RM algorithm and the
extensions made to allow performing constraint-based redescription mining. In addition, we
describe what reasons motivated us for the use of a redescription accuracy evaluation measure
and a specific query language used to construct redescriptions.
Choice of redescription mining algorithm. To create redescriptions, we used the
CLUS-RM algorithm [29, 30] based on Predictive Clustering trees (PCT) [42, 43]. PCTs allow
clustering on both target and descriptive space. By using their multi-label and multi-target
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capability one can use multiple (or all) nodes in a given tree simultaneously to produce rede-
scriptions. Due to the property of inductive transfer [46], multi-target classification can out-
perform single-target classification, which improves the overall accuracy of produced
redescriptions. The CLUS-RM algorithm incorporates a redescription set optimization proce-
dure (a novelty compared to other redescription mining approaches), which uses the large
number of diverse redescriptions produced to optimize a redescription set of user-define size.
Using a large number of produced redescriptions in the optimization process increases the
quality of the redescription set presented to the user. The optimization process evaluates rede-
scriptions according to accuracy, significance and redundancy (with respect to redescription
support sets and attributes contained in redescription queries).
Since our data contain missing values, we could only use the CLUS-RM or the ReReMi
algorithm to find redescriptions. Given our goal of using the produced redescription sets to
perform further statistical analysis, there are several reasons that motivate the use of CLUS-RM
as the redescription mining algorithm in this work. CLUS-RM has the ability to produce
potentially large sets of redescriptions that can be used to perform statistical analysis (e.g. of
obtained associations). Multiple different redescriptions containing the same attribute pair
and describing different subsets of instances reinforce the importance of frequently co-occur-
ring attributes. CLUS-RM can constrain redescription support set size to an interval, which
provides experts with a range of associations (hypotheses), from general (intervals containing
larger support set size) to more specific (intervals containing smaller support set size). It can
also produce redescription sets of user defined size which allows creating sets that contain
equal number of members per support interval for further statistical analysis. Because of this,
association statistics will not be constructed only from very general or very specific redescrip-
tions, but from redescriptions covering a whole range of different support sizes. The experi-
ments with CLUS-RM [30], and its extension [44], as well as the integration of the CLUS-RM
into a redescription mining framework for redescription set construction [45], show that the
produced redescription sets were fully competitive with other state-of-the-art solutions, and in
some cases (as when only conjunctions are used in redescription query construction), the
resulting redescription sets can even contain significantly more accurate and diverse
redescriptions.
To obtain the results presented in this work, we required the constraint-based redescription
mining capability, mostly using one attribute as constraint. However, developing a constraint-
based methodology that is able to use multiple attributes (instances) as constraint was straight-
forward and is also presented as a part of this work. The proposed extensions include several
modes of constraint-based redescription mining (CBRM) that allow exploring interactions of
multiple attributes from different views with Boolean, categorical and numerical variables,
extending the state-of-the-art in CBRM. Instance level constraints can be incorporated in anal-
ogous fashion.
The one-attribute CBRM capability of Siren [47] allows selecting one attribute as constraint
and defining its numerical interval (for numerical attributes). The resulting redescription set is
comprised of redescriptions that are obtained by extending the initial query supplied by the
user. When compared to this limited CBRM capability of Siren, the CLUS-RM extension oper-
ates in a fully automated constraint-based setting (allowing multiple attributes as constraints).
Also, it is not necessary to manually select numerical bounds as is currently the case in Siren.
In general, performing interactive constraint-based redescription mining can demand signifi-
cant effort and time from the domain expert (in addition to examination of computed rede-
scriptions, which also needs to be done in our approach), but can potentially enable tuning the
algorithm better to find information about some specific, targeted problem.
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Analysis and exploration of precomputed redescription sets, based on multiple different
redescription criteria, exploration of different attribute associations and groupings of instances
based on a produced redescription set is also possible with the tool InterSet [48].
Choice of redescription accuracy measure. Since the data contains missing values, we
used the query non-missing Jaccard index, introduced in [30], and further explained in [45] to
evaluate redescriptions. The query non missing Jaccard index is defined as:
Jqnmðq1; q2Þ ¼
jE1;1j
jE1;1j þ jE?;1j þ jE1;?j þ jE0;1j þ jE1;0j
Query non-missing Jaccard index evaluates instances as being a part of redescription sup-
port set only if there is enough information in the data (given the query language) to deduce
that these instances satisfy the conditions of both redescription queries. The construction of
this measure is guided by the principle that the query cannot contain an instance in its support
set if it cannot be evaluated due to missing values. Because of this, the measure does not penal-
ize the score with instances contained in the sets E?,?, E0,?, E?,0 and rather treats them as if they
were contained in the set E0,0 but penalizes the score with instances contained in the sets E?,1
and E1,? and treats them as if they are contained in sets E1,0 and E0,1.
Query non-missing Jaccard index has been designed to trade-off between the pessimistic
and the optimistic Jaccard index [36], which are each forcing opposite extreme values and are
thus leading to less realistic estimates of the true Jaccard index. Query non-missing Jaccard
index is optimistic because it does not penalize the score with instances that are not described
by one query and cannot be evaluated by the other query, due to missing values (E?,0, E0,?). On
the other hand, it is pessimistic, since it penalizes the score with instances that are described by
one redescription query, but cannot be evaluated by the other, due to missing values (E1,? and
E?,1). Redescription accuracy estimates provided by query non-missing, pessimistic and opti-
mistic Jaccard index have already been compared experimentally in [45].
Choice of a query language. In this work, our redescriptions consist exclusively of con-
junctive queries. Queries containing only conjunction operators are easier to understand and
usually shorter than those containing combination of all operators. In redescriptions with que-
ries containing only conjunction operators, every attribute used in its queries must describe all
instances from redescription support set. Thus, such redescriptions discover stronger associa-
tions between attributes than redescriptions with queries containing all operators. These rea-
sons make us believe that applying CLUS-RM with restriction to use of conjunctions to ADNI
data is the right choice which may reveal useful medical hypotheses that can be further devel-
oped by the domain experts. Described query language is similar to the one used in bi-direc-
tional association rules which can, for instance, be produced by the two-view data association
discovery approach, discussed in the Introduction section. In general, using negation and dis-
junction operators in redescription construction can increase the diversity and accuracy of
produced redescriptions, but it can also make them more difficult to understand for domain
experts.
CLUS-RM algorithm description
All experiments were performed with the CLUS-RM redescription mining algorithm [29, 30],
presented in Algorithm 1. CLUS-RM uses PCTs [43] to find descriptions of groups of
instances (i.e. subjects, as is the case in our medical study).
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Algorithm 1 The CLUS-RM algorithm
Require:Firstview (W1), Secondview (W2), maxIter,QualityconstraintsQ
Ensure:A set of redescriptionsR
1: procedureCLUS-RM
2: ½Wð0Þ1 ;W
ð0Þ
2   createInitalData(W1, W2)
3: ½PWð0Þ
1
;PWð0Þ
2
  createInitialPCTs(Wð0Þ1 ,W
ð0Þ
2 )
4: ½rWð0Þ
1
; rWð0Þ
2
  extractRulesFromPCT(PWð0Þ
1
;PWð0Þ
2
)
5: for Ind 2{1, . . ., maxIter}do
6: ½WðIndÞ1 ;W
ðIndÞ
2   constructTargets(rWðInd  1Þ
1
, rWðInd  1Þ
2
)
7: ½PWðIndÞ
1
;PWðIndÞ
2
  createPCTs(WðIndÞ1 ;W
ðIndÞ
2 )
8: ½rðIndÞW1 ; r
ðIndÞ
W2   extractRulesFromPCT(PWðIndÞ
1
;PWðIndÞ
2
)
9: for (Rnew 2 rWðIndÞ
1
QrWðInd  1Þ
2
[ rWðInd  1Þ
1
QrWðIndÞ
2
) do
10: R addReplaceDiscard(Rnew;R)
11: R minimizeQueries(R)
12: returnR
The presented algorithm pseudocode describes the CLUS-RM functionality in case only
conjunction logical operators are used to create redescription queries. The extended version of
the algorithm pseudocode for the case in which conjunction, negation and disjunction logical
operators can be used in redescription query construction is described in [30] and supplemen-
tary document S18 File.
The algorithm consists of four main parts: 1) Initialization, 2) Query creation (divided in
query construction 2.1 and query exploration 2.2), 3) Redescription creation and 4) Redescrip-
tion set optimisation.
1) In the initialization phase (line 2 in Algorithm 1), the algorithm makes a copy of each
instance from the original dataset and shuffles the attribute values for the copies. For each
attribute, the algorithm selects a random instance from the dataset and copies its value for the
selected attribute to the target copy (value of one instance from the original dataset can be cop-
ied multiple times). This procedure breaks correlations between attributes in the copied
instances. Each instance from the original dataset is assigned a target value 1.0 and each artifi-
cially created instance a target value 0.0. It is possible to use the PCT algorithm to create initial
clusters, from such dataset, by distinguishing between original instances and copies containing
shuffled values (line 3 in Algorithm 1). The described procedure is repeated independently for
both views contained in the dataset.
2.1) Each node in the obtained PCTs represents a cluster. These nodes are transformed to
rules (line 4 in Algorithm 1) which are valid for the corresponding group of instances. More
details about transforming PCTs to rules can be seen in [49].
2.2) The next step is to describe the same groups of instances, as those described by the pro-
duced rules, with the second attribute set (lines 6−8 in Algorithm 1). To do this, for each
instance of the original dataset, the algorithm constructs a set of target variables containing
equal number of targets as number of rules constructed using the first set of attributes (for
more details see [30]). The instance has a target value 1 on position j if it is described by the j-
th rule from a set of rules constructed on the first set of attributes, otherwise the value is 0.
Instances for which information is missing, making it impossible to determine the member-
ship in support set of the query are also labelled with 0. We use the multi-target classification
and regression capability of PCT to construct clusters on different views containing similar
instances. The procedure is repeated by creating initial rules on the second view and describing
similar sets of instances by using attributes from the first view.
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3) Once the algorithm obtains rules for both views, it combines them by computing the
Cartesian product of two rule-sets (line 9 in Algorithm 1). Each redescription is evaluated with
various user predefined constraints (such as minimal redescription accuracy, minimal support,
maximal p-value, contained in a set of redescription quality constraints Q), to select candidates
for redescription set optimization.
4) Each redescription satisfying all user-defined redescription quality constraints is a candi-
date for redescription set optimization (line 10 in Algorithm 1). Satisfactory redescriptions are
added to the redescription set, in the order of creation, until the maximal number of redescrip-
tions (user-defined parameter) is reached. When this number is reached, the algorithm com-
putes the score difference, defined in [29, 30], between the new redescription and every
redescription already contained in the redescription set based on redescription score. The
score of some redescription R 2 R, based on its support set and a redescription set R, is com-
puted as:
redScoreInstðRÞ ¼
P
i2suppðRÞðcoverInstRnRðiÞÞ
P
i2DcoverInstRðiÞ
where coverInstRðiÞ ¼ jfR 2 R; i 2 suppðRÞgj denotes the number of times, the instance i is
described by redescriptions from the redescription set R. The denominator of a score redScor-
eInst(R) can be also written as
P
R2RjsuppðRÞj. Similarly, the redescription score:
redScoreAttrðRÞ ¼
P
a2attrðRÞðcoverAttrRnRðaÞÞ
P
a2attrðDÞcoverAttrRðaÞ
is based on attributes contained in redescription queries, where coverAttrRðaÞ ¼ jfR 2 R; a 2
attrðRÞgj denotes the number of times attribute a is used in queries of redescriptions contained
in R. The denominator of a score redScoreAttr(R) can be also written as
P
R2RjattrðRÞj.
The score of a newly created redescription Rnew is computed in the same way as the score
for some R 2 R but using frequencies for all redescriptions contained in the set R in the
numerator of redScore and redScoreAttr.
The error score is computed as errSc(R) = 1.0 − J(R) and the final redescription score is
computed as:
scðRÞ ¼ a1  errScðRÞ þ a2  redScoreInstðRÞ þ a3  redScoreAtðRÞ
where ai 2 ½0; 1;
P3
k¼1 ai ¼ 1. Lower total redescription score is favourable because it implies
smaller error in redescription accuracy and smaller level of instance and attribute redundancy
with respect to other redescriptions from the set R. The user—defined weights αk regulate
importance of different scores which affect the properties of the resulting redescription set. In
this work, we use ak ¼
1
3
. Redescription contained in the redescription set with the highest
score difference with the newly created redescription is replaced thus improving the overall
redescription set quality. At each redescription exchange all frequency scores are updated.
The minimization procedure introduced in [30] and performed in line 11 of Algorithm 1 is
a heuristic procedure designed to reduce the size of redescription queries by removing redun-
dant attributes (attributes that can be removed without changing redescription accuracy). It is
performed individually on each redescription of the resulting redescription set.
Constraint-based redescription mining. In this work, we extended the CLUS-RM algo-
rithm to a constraint-based redescription mining setting. The algorithm incorporates
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constraints in redescription creation and one additional score in the optimization function
used for redescription set creation. Necessary CBRM extensions of the CLUS-RM algorithm,
when conjunction, negation and disjunction operator can be used in redescription query con-
struction are described in supplementary document S18 File.
We present the attribute level constraints useful for gaining knowledge as demonstrated in
this work. Constraints involving instances can be introduced in the analogous fashion by
using redescription support set (supp(R)) instead of attribute set (attrs(R)) in formulas (1), (2)
and (3).
Constraint-based redescription mining, first defined in [31], allows placing constraints on
attributes that must occur in redescription queries or instances that must be contained in rede-
scription support set. The constraints are in the form C ¼ fC1;C2;    ;Cng, where each con-
straint Ci specifies a set of attributes that must occur in redescription queries or a set of
instances that must be contained in redescription support set. In the original formulation, at
least one constraint Ci must be satisfied by a redescription (contain all attributes or instances
specified in the set) to be presented to the user. We denote this original definition as strict con-
strained-based redescription mining and mostly use it in our study. In practice, various relaxed
versions of constrained-based redescription mining might be useful. In the continuation, we
specify one existing (strict) and two newly defined (soft and suggested) modes of constraint-
based redescription mining (focusing only on attribute constraints):
1. Strict constraint-based redescription mining: there must exist at least one constraint Ci 2 C
such that all defined attributes occur in redescription queries.
2. Soft constraint-based redescription mining: there must exist at least one constraint Ci 2 C
such that a part of defined attributes occurs in redescription queries. Satisfying larger por-
tion of constraints is favoured by the redescription evaluation score.
3. Suggested constraint-based redescription mining: defined constraints are used as sugges-
tions that increase the overall redescription score depending on the number of satisfied
constraints, however high quality redescriptions not satisfying any of these constraints can
also enter redescription set if their total score is high enough.
Strict constraint-based redescription mining can be used when the expert already has a
hypothesis (obtained through domain knowledge and extensive experimentation) and wants
to explore the specified associations in more detail. Soft constraint-based redescription mining
can be used when a set of attributes of interest has been determined (by applying the combina-
tion of domain knowledge and experimentation) but it is not clear which interactions from the
set should be fully explored. Thus, further study of their interactions is needed to form, refine
or confirm the expert hypothesis. Suggested constraint-based redescription mining can be
used when the expert, knowing the research domain (having a priori knowledge about the
problem), selects a set of attributes that are known or suspected to be (currently) more inter-
esting for exploration, though at current stage there is no immediate focus on any particular
hypothesis.
To allow constraint-based redescription mining, we extend the CLUS-RM algorithm by
adding a new set of constraints C containing the user-defined attributes of special interest and
a type of CBRM used (parameter T ). Line 9 of Algorithm 1 is changed to
Rnew 2 ðr
ðindÞ
W1 ÞfC;T gQðr
ðindÞ
W2 ÞfC;T g. Thus, redescriptions are created only by combining those que-
ries that satisfy predefined constraints. For each redescription Rnew, we apply query minimiza-
tion procedure before using redescription set optimization (defined in line 10 of Algorithm 1).
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If query minimization procedure removes any of the key constraint attributes, defined in set C
of CBRM, the created redescription is discarded.
In addition, CLUS-RM is extended with a new score scConstr, which is used in suggested
constraint-based redescription mining to increase the overall score of a redescription satisfying
user-defined attribute constraints. The score is defined as:
scConstrðRÞ ¼
1
2
max
jattrsðRÞ \ Cij
jCij
; Ci 2 C
 
þ
1
2

jattrsðRÞ \ ð[iCiÞj
jattrsðRÞj
ð1Þ
The first term in the score rewards redescriptions satisfying higher fraction of constraints
from some set Ci. Due to the fact that more disjoint or partially overlapping constraint sets can
be given and the fact that some redescriptions can satisfy parts of larger number of constraint
sets Ci, we take the maximum score achieved among constraint sets as a quality of redescrip-
tion—thus favouring compliance with larger number of constraints from a single constraint
set. The second term favours redescriptions that, among the attributes contained in their que-
ries, have larger fraction of attributes of interest to the user. Here, we reward satisfied con-
straints from any constraint set defined by the user.
The score used for soft constraint-based redescription mining is defined as:
redScoreSoft ¼
( scConstrðRÞ if 9Ci 2 C; attrsðRÞ \ Ci 6¼ ;
  1 otherwise
ð2Þ
Similarly, the score used for strict constraint-based redescription mining is defined as:
redScoreStrict ¼
(
1 if 9Ci 2 C; attrsðRÞ \ Ci ¼ Ci
  1 otherwise
ð3Þ
Higher scores denote higher level of agreement of redescriptions with the imposed constraints
(redescriptions with higher score are thus preferable).
Finally, redescription score sc(R) is extended to:
scðRÞ ¼ a1  errScðRÞ þ a2  redScoreInstðRÞþ
þa3  redScoreAtðRÞ þ a4  ð1   redScoreConstðRÞÞ
where ai 2 ½0; 1;
P4
k¼1 ai ¼ 1 and redScoreConst(R) denotes any variant of the constraint-
based score chosen by the user. Redescriptions with the score value of1 are not allowed to
enter redescription set.
With the extension introduced above, the CLUS-RM is the only redescription mining algo-
rithm capable of performing fully automated constraint-based redescription mining on cate-
gorical, numerical and data containing missing values with more than one attribute constraint.
Experiments and results
In this section, we present the experimental setup and some selected results obtained through
the analyses of the produced redescription sets.
Experiments
Our main goal was to study clinical and biological attributes, and to find interesting relations
among them. To retrieve maximum information from and to obtain deeper insight into the
data, we divided redescriptions by the number of described subjects and used the diagnosis of
the level of cognitive impairment to further assess the relevance and interestingness of the
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obtained redescriptions. For each dataset, we created four redescription sets containing rede-
scriptions with different supports, describing [5, 10], [11, 39], [40, 99] and at least 100 subjects.
The maximum support threshold was set to d jDi j
2
e subjects contained in the dataset Di, i 2 {1,
2,3}. We are interested in re-describing subsets of subjects with some level of cognitive
impairment and using cognitively normal subjects as a control group. Studying different bio-
logical, clinical attributes and their interactions in the context of different levels of cognitive
impairment is also of high interest. Higher homogeneity of described subjects increases the
amount of information obtained about different changes in biological and clinical attributes
occurring as a result of different level of cognitive impairment. Developing an approach with a
combined properties of redescription mining and subgroup discovery may also be interesting
in this setting, but is beyond the scope of this work. Each set contains 100 redescriptions with a
minimal Jaccard Index of 0.2 and a maximal p-value of 0.01. Allowed support intervals, as well
as other parameter limits were found through experimentation. Redescriptions contained up
to 8 attributes per query.
The same support intervals were used to create redescriptions on each dataset. This allows
making easier comparisons of redescriptions and statistics of attribute co-occurrence across
different datasets. Distribution analysis of redescription quality measures, in the produced
redescription sets, reveals potentially interesting datasets, attributes and support intervals.
Since PAPP-A showed interesting associations with cognitive impairment in the experi-
ments described above, we performed constraint-based redescription mining with the same
algorithmic parameters but focusing redescription search on redescriptions containing preg-
nancy associated plasma protein A (PAPP-A) in the redescription queries. We created one
redescription set containing 100 redescriptions describing at least 100 subjects.
Redescription accuracy and homogeneity analysis
We merged the four sets of redescriptions, of different supports, created on each dataset (D1,
D2, D3) and formed one larger redescription set (RS) per dataset, denoted R1;R2;R3 (see Fig
2). For the obtained redescriptions, contained in the corresponding redescription sets
(R1;R2;R3), we analysed the homogeneity of the described subsets of subjects with respect to
the degree of cognitive impairment (CN, SMC, EMCI, LMCI and AD) by computing the
entropy of described subject’s medical diagnosis (demonstated in Fig 2).
The entropy was computed for the support set of each redescription by using the package
entropy developed for the programming language R. The package allows estimating Shannon’s
entropy (H ¼  
PN  1
i¼0 pi  log2ðpiÞ) [50] of some finite set of probabilities obtained from the
observed counts (occurrence frequencies of each level of cognitive impairment in the rede-
scription support set). In this use-case, N equals the number of different target classes occur-
ring in the support set of a redescription. Probability pi is computed as pi ¼
jtargeti \ suppðRÞj
jsuppðRÞj , where
targeti, i 2 {0, . . ., N − 1} denotes a set of entities with target label i. Characteristics of redescription
sets produced with different support intervals (1., 2., 3., 4. in Fig 2), can be seen on a plot show-
ing entropy distributions (i in Fig 2) and distributions of redescriptions’ Jaccard index (ii in
Fig 2).
Due to the smaller diversity in target classes (containing no SMC subjects and only 1 EMCI
subject), it was easier to distinguish between different groups of subjects on dataset 3 (which is
illustrated in Fig 2) than on the other two datasets. On dataset 3, we obtained many clusters of
various size, homogeneous with respect to medical diagnosis, which gives us confidence that
we found attribute combinations and numerical intervals useful for the analysis and under-
standing of cognitive impairment connected to AD.
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The entropy increases with the increase of the number of described subjects, while the Jac-
card index shows stronger associations in redescriptions with support in the first (|supp(R)|
100 in Fig 2) and the last interval (|supp(R)| 2 [5, 10] in Fig 2). Redescriptions describing the
smallest number of subjects (the last interval) use larger number of attributes with very specific
numerical intervals to isolate groups of subjects that are very homogeneous with respect to the
medical diagnosis and describe many different groups of subjects suffering from severe cogni-
tive impairment (LMCI, AD). In contrast, many accurate redescriptions (in the first interval)
use larger numerical intervals, thus often describing subjects with various levels of cognitive
impairment. Additional reason for higher accuracy in this interval compared to the middle
two intervals is the detection of highly accurate redescriptions describing subgroups of CN
subjects. Missing values in the data and potential noise, occurring from the errors in measure-
ments and data processing, negatively affect the Jaccard index.
Analyses based on examination of redescription sets
Redescription set analyses, which included: a) the examination and expert evaluation of indi-
vidual redescriptions, b) the distribution analysis of level of dementia for the described subjects
of these redescriptions, c) comparative analyses of attribute value distribution between differ-
ent subsets of subjects (LMCI/AD vs CN or supp(R) vs CN), allowed us to find useful informa-
tion related to subjects with cognitive impairment.
From the clinical attributes, we noticed that ADAS, MOCA, Geriatric Depression Scale,
Rey Auditory Verbal Learning Test (especially the percent forgetting score), and Mini-Mental
State Exam (MMSE) occurred frequently in queries of obtained redescriptions that describe
subjects suffering from various degrees of cognitive impairment. Nevertheless, there were
instances where some CN subjects fell in the identified intervals of values for these attributes.
Attributes connected to Clinical Dementia Rating distinguished well between CN subjects and
those with different degrees of cognitive impairment. Redescriptions mostly contained the
attributes CDMEMORY, CDGLOBAL and CDR-SB (clinical dementia rating sum of boxes).
From the biological attributes, we often encountered attributes connected to brain volume,
hippocampus, various blood and urinary tests (attributes HMT and RCT), intracranial volume
(ICV), 18fluorodeoxyglucose—positron emission tomography (FDG-PET) and 18F-florbetapir
(AV45). These attributes have been studied before by Gamberger et al. [3, 13]. We noticed that
the biological attribute SPARE_AD (Spatial Pattern of Abnormalities for Recognition of Early
AD) correlated with subject’s diagnosis very well and occurred frequently in redescriptions
constructed on dataset 3 that contains it. Also, the gene variant APOE ε4 was present exclu-
sively in redescriptions describing subjects diagnosed with LMCI and AD.
We report several attributes, discovered during our analyses, for which we detected varia-
tions in levels connected to AD or discovered interesting subgroups of patients with signifi-
cantly different distribution of values for a given attribute compared to CN subjects.
Difference in distribution is measured with three different statistical tests: a) Anderson-Dar-
ling (ADT) test [51, 52], Kolmogorov-Smirnov (KST) test [53, 54] and Mann-Whitney U
(MWUT) test [55]. For Anderson-Darling we perform two-sided test and report simulated
Fig 2. Entropy (i) and Jaccard index (ii) value distributions for the redescription sets created on each dataset (first
dataset—D1 at the top, third dataset—D3 at the bottom). For a dataset Di, i 2 {1, 2,3}, we create four redescription sets Ri;1  
Ri;4 so that the number of described subjects in each redescription (from a particular redescription set) falls in the corresponding
interval shown on the y-axis (boxplots representing distributions for each interval are coloured in different color). Each
redescription set Ri;j ; i 2 f1; 2; 3g; j 2 f1;    ; 4g contains 100 redescriptions.
https://doi.org/10.1371/journal.pone.0187364.g002
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(ps) and asymptotic (pa) p-values, while for Kolmogorov-Smirnov and Mann-Whitney U test
we report p-values, obtained by performing one-sided tests, and the observed direction of the
shift of distribution. Alternative hypothesis (a), for one-tailed tests have two possible forms:
a equals ( = ) less (l), or (a) = greater(g). Depending on the choice of statistical test,
the alternative hypothesis have different meaning (explained in S17 File). Simulated p-value in
ADT are obtained with default parameters (1000 simulations). Short motivation for the used
statistical tests, providing references to implementations and meaning of the chosen alterna-
tive, for the used one-sided tests, is available in supplementary document S17 File. Tests of sta-
tistical significance of difference in distribution between one selected example group and a
group of CN subjects for all mentioned attributes is displayed in Table 5. Information about
attributes with statistically significant difference in distribution between AD/LMCI and CN
subjects is reported in Table 6.
By observing redescriptions describing very homogeneous groups of subjects with high
level of cognitive impairment (LMCI and AD), we discovered groups where testosterone levels
(TSTSTRNT) were significantly decreased. Although some studies (e.g. Zhao et al. [56]) and
meta-analyses showed no differences in plasma levels of testosterone between AD and
matched controls (e.g. Xu et al. [57]), some studies, such as the one of Hogervorst et al. [58]
and Lv et al. [59], found low free testosterone level to be an independent risk factor for AD.
Plasma testosterone levels display circadian variation, peaking during sleep, and reaching a
lowest level in the late afternoon, with a superimposed ultradian rhythm with pulses every 90
min reflecting the underlying rhythm of pulsatile luteinizing hormone (LH) secretion [60].
The increase in testosterone during sleep requires at least 3 hours of sleep with normal sleep
architecture. However, since noradrenergic locus coeruleus and serotonergic dorsal raphe
nucleus are among the first neurons affected by neurofibrillary tau pathology, their changes
lead to the early and prominent deterioration of the sleep-wake cycle in AD (for a review, see
sˇimić et al. [61]), which may add to a reduction of testosterone levels with advancing age.
Experimental data obtained in animal models of AD suggest that low levels of testosterone
increase Aβ and tau pathology through both androgen and estrogen pathways (testosterone is
metabolized in the brain into androgen dihydrotestosterone, DHT, and 17β-estradiol, the E2
estrogen) [62, 63].
Table 5. Attributes analysed in this section with corresponding example redescription containing this attribute. For each selected attribute we pres-
ent example redescription that describes subjects with statistically significant difference in attribute value distribution compared to a group of CN subjects.
Attribute D R |E1,1| File ADT KST MWUT
pa ps a p a p
ANG2 D3 R45 46 S14 4.1  10−3 0 l 2.7  10−6 g 4.7  10−6
APOAII D3 R37 55 S14 7.3  10−15 0 g 1.7  10−11 l 4.2  10−13
BNP D3 R96 48 S14 5.7  10−3 0 l 0.02 g 0.15
CNTF D3 R56 33 S13 0.03 0.03 l 0.02 g 0.02
TSTSTRNT D3 R85 366 S15 5  10−6 0 g 0.002 l 0.05
INSULIN D3 R90 5 S12 0.01 0.01 l 0.06 g 0.01
LEPTIN D3 R72 24 S13 9.4  10−6 0 g 5.1  10−6 l 7.4  10−6
MCRPHMIF D3 R31 6 S12 9  10−5 0 l 4.2  10−4 g 2.3  10−4
PAPP-A D3 R39 327 S16 3  10−6 0.0 l 4.8  10−4 g 1.8  10−5
PPP D3 R43 8 S12 8.8  10−3 0.13 l 0.02 g 0.008
SPARE_AD D3 R37 155 S15 1.2  10−28 0.0 l 2.2  10−16 g 2.2  10−16
https://doi.org/10.1371/journal.pone.0187364.t005
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Unlike previous scarce data and negative correlation [64], we also found increased levels of
ciliary neurotrophic factor (CNTF) in plasma in several redescriptions describing subjects
with high level of cognitive impairment, together with decreased levels of leptin. The difference
in distribution of leptin level between groups of AD/LMCI patients and CN subjects is signifi-
cantly different (lower for AD and LMCI patients). This is in agreement with the results of
Marwarha and Ghribi [65], showing that lower leptin levels detected in AD subjects can be a
possible target for developing supplementation therapies for reducing the progression of AD.
Some groups of subjects (such as R45 from S14 File) had significantly increased levels of plasma
angiopoietin-2 (ANG2). This is in agreement with research by Thirumangalakudi et al. [66]
and research by Grammas et al. [67], that revealed elevated expression of angiopietin-2 in the
brains of AD subjects and the transgenic AD mice, respectively.
Increased levels of plasma brain natriuretic peptide (BNP) were found in several redescrip-
tions containing subjects with severe cognitive impairment. Previous research [68] suggested
that this peptide has more significant association with vascular dementia than with AD. This
could suggest either that this group of subjects, described by redescriptions containing BNP
attribute, suffered from both types of dementia (mixed dementia), or that these cases do not
suffer from AD but indeed suffer from vascular dementia. Distributions of level of BNP are sig-
nificantly different, in dataset D3, between groups of LMCI/AD and CN subjects.
Finally, we also found alteration in plasma levels of several other attributes, whose relation-
ship with AD has already been shown in the literature. These include increase in serum apoli-
poprotein B (APOB) [69], pancreatic polypeptide (PPP) [70, 71] and for very small groups, the
increase of plasma insulin [72] and the CSF macrophage migration inhibitory factor
(MCRPHMIF) [73] in AD brain. Fas (CD95) ligand (FASL) levels are found to be significantly
decreased in LMCI patients compared to AD and CN subjects in our dataset. Levels are also
lower in AD patients than in CN subjects but the difference is not statistically significant.
Although one study suggests the upregulation of FASL in AD brain [74], the levels and varia-
tions seem to heavily depend on the part of the brain. For instance, FASL levels are found to be
significantly decreased in hippocampus [75] in patients suffering from AD. Several groups of
LMCI/AD patients with significantly lower levels of APOAII compared to the CN subjects
were detected (which corresponds to research performed in [76, 77]). The difference in value
Table 6. Analysed attributes with statistically significant difference in value distribution between groups of LMCI or AD patients and CN subjects.
Attribute D Type ADT KST MWUT
pa ps a p a p
APOAII D3 LMCI vs CN 4.6  10−11 0 g 1.1  10−9 l 3.1  10−10
D3 AD vs CN 3.3  10−7 0 g 8.4  10−5 l 3.3  10−7
APOB D3 AD vs CN 0.03 0.04 l 0.03 g 0.02
ANG2 D3 LMCI vs CN 2.6  10−4 0 l 4.8  10−3 g 1.5  10−4
BNP D3 LMCI vs CN 9.2  10−8 0 l 1.8  10−5 g 1.2  10−6
D3 AD vs CN 6  10−7 0 l 1.3  10−5 g 1.2  10−6
FASL D3 LMCI vs CN 3  10−5 0 g 0.001 l 2  10−5
LEPTIN D3 LMCI vs CN 1.2  10−3 0 g 6  10−3 l 4.7  10−4
D3 AD vs CN 0.05 0.05 g 0.08 l 0.02
PAPP-A D3 LMCI vs CN 7.2  10−4 0.001 l 1.3  10−3 g 3.4  10−4
D3 AD vs CN 6.1  10−6 0 g 1.1  10−4 l 8.3  10−5
PPP D3 LMCI vs CN 6.2  10−3 0.005 l 0.009 g 0.003
D3 AD vs CN 2.5  10−3 0.001 l 0.007 g 1.5  10−3
https://doi.org/10.1371/journal.pone.0187364.t006
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distribution in dataset D3 is significant between groups of LMCI/AD patients and CN subjects.
Alterations in the levels of the PAPP-A attribute between CN subjects and LMCI/AD patients
are very interesting (see Tables 5 and 6). The PAPP-A levels rise in LMCI subjects than drop
significantly in AD subjects. This very property has been already detected in [78].
For each redescription set, we extracted one interesting, statistically significant redescrip-
tion, and displayed its queries, along with the diagnosis distribution of the subjects described
by this redescription (as shown in Fig 3).
The three redescriptions (as shown in Fig 3 from top to bottom) describe 602, 118 and 365
subjects, respectively with different proportion of EMCI, LMCI and AD diagnosis. They are
statistically significant and describe 46%, 20% and 62% of all subjects with some level of cogni-
tive impairment contained in the corresponding dataset. Their queries mostly contain well
known attributes listed in Table 2 and in S1–S3 Files. The clinical attributes contained are
memory score (CDMEMORY), Clinical Dementia Rating Scale Sum of Boxes (CDRSB),
judgement and problem solving score (CDJUDGE), Alzheimer’s Disease Assessment Scale
(ADAS), Mini-Mental State Exam (MMSE). The biological attributes used contain neutrophils
(HMT8), 18F-florbetapir (AV45), 18fluorodeoxyglucose—positron emission tomography
(FDG-PET), Spatial Pattern of Abnormalities for Recognition of Early Alzheimer’s disease
(SPARE_AD) and Pregnancy-Associated Protein-A (PAPP-A) measurements.
Pairwise attribute association analysis based on co-occurrences
In this section, we present results of attribute association analyses based on attribute co-occur-
rences in queries of redescriptions contained in our redescription sets. To obtain these associa-
tions, we studied the attribute co-occurrence frequencies in redescriptions contained in
redescription sets R1;R2 and R3. We focused on redescriptions describing subjects with some
level of cognitive impairment. Co-occurrence frequencies were computed separately for pairs
Fig 3. Example redescriptions (one for each dataset), each describing at least 100 subjects. All subjects described
are diagnosed with EMCI, LMCI or AD. Attribute explanations can be seen in Tables 2 and 3 (P denotes PAPP-A and FDG
denotes FDG-PET).
https://doi.org/10.1371/journal.pone.0187364.g003
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of attributes contained in views bio-bio, clin-clin and bio-clin, where bio denotes the view con-
taining biological and clin denotes the view containing clinical attributes. Finally, we merged
all redescriptions computed on all three datasets to obtain global information about pairwise
attribute associations (set R1 [R2 [R3). We do this for bio-bio, clin-clin and bio-clin combi-
nations of views. Besides the associations, we also computed the pairwise attribute correlations,
by using values of all subjects in the corresponding dataset for the selected pair of attributes,
and the statistical significance of these correlations. For each attribute we performed the Kol-
mogorov-Smirnov test to assess if its values, for subjects contained in the dataset, follow nor-
mal distribution. If we obtained p-values smaller than 0.05 for both attributes in the pair, we
computed Pearson correlation coefficient [79], otherwise we computed the Spearman’s corre-
lation coefficient [80] and the appropriate p-value of the corresponding significance test.
Spearman’s test was also used to compute correlations involving attributes with ordinal values.
A short list of top 5 pairwise associations (by co-occurrence) between attributes contained
in the analysed datasets is provided in Tables 7, 8 and 9.
Table 7 shows high association between FDG-PET and the volume of the hippocampus, the
entorhinal cortex, as well as an attribute related to the volume of the lateral ventricles. High
association was also found between intracranial volume and creatine kinase levels (CKMB).
This enzyme is present in greatest amounts in skeletal muscle, myocardium, and brain. The
FDG-PET attribute often occurred in the same descriptive rules as the attribute measuring the
level of vitamin B12 (BAT126). Administering of vitamin B12 is known to have beneficial
effects on cognition when there is insufficient level of B12 in the organism [81, 82]. The inci-
dence of AD increases with age and in fact, older adults often show deficiency of vitamin B12,
Table 7. The top five associations between pairs of biological attributes as measured by their co-occurrence in redescription queries. Attribute cor-
relations for a redescription set Ri are computed on dataset Di. P denotes the Pearson correlation coefficient and S denotes the Spearman’s correlation coeffi-
cient. Ru ¼ R1 [R2 [R3. Correlations for attribute pairs from the redescription set Ru are computed on the largest dataset containing both attributes.
Pairwise associations and correlations between biological attributes
RS Attribute pair Co-occurrence Test Correlation p-value
R1 Hippocampus, FDG-PET 111 P 0.42 <2.2  10−16
FDG-PET, Entorhinal 106 P 0.35 <2.2  10−16
FDG-PET, Ventricles 52 S −0.39 <2.2  10−16
FDG-PET, ICV 46 S −0.39 <2.2  10−16
FDG-PET, AV45 42 S −0.37 <2.2  10−16
R2 FDG.PET, Hippocampus 86 P 0.4 <2.2  10−16
FDG-PET, Entorhinal 76 P 0.31 <2.2  10−16
FDG-PET, AV45 52 S −0.37 <2.2  10−16
FDG-PET, RCT14 45 S 0.124 0.0003
FDG-PET, BAT126 31 S −0.007 0.42
R3 SPARE_AD, PAPP-A 66 S −0.05 0.1
SPARE_AD, Entorhinal 39 S −0.51 <2.2  10−16
PLMNRARC, PAPP-A 18 S −0.05 0.14
SPARE_AD, TNC 17 S 0.09 0.14
PAPP-A, Entorhinal 15 S 0.08 0.039
Ru Hippocampus, FDG-PET 197 P 0.42 <2.2  10−16
FDG-PET, Entorhinal 182 P 0.35 <2.2  10−16
FDG-PET, AV45 94 S −0.37 <2.2  10−16
FDG-PET, Ventricles 68 S −0.39 <2.2  10−16
FDG-PET, ICV 67 S −0.39 <2.2  10−16
https://doi.org/10.1371/journal.pone.0187364.t007
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mainly due to the impaired vitamin B12 uptake in the gastrointestinal tract [83]. AD patients
also have increased homocysteine levels in the blood. Since homocysteine is directly associated
with brain atrophy, it is possible that vitamin B12 supplementation (that reduces homocysteine
levels) can actually slow the progression of brain atrophy [81]. However, since meta-analyses
failed to prove [84, 85] the connection of vitamin B12 supplementation with homocysteine lev-
els and improved cognition, further studies should be conducted to resolve this issue. The cor-
relation between FDG-PET and B12 values in our dataset was not statistically significant,
though it may be more pronounced on a subset of subjects (for instance those above a certain
age). It has been reported [86] that diagnosis based on FDG-PET can lead to false diagnosis of
AD, where subjects can be cognitively normal or have cognitive impairment due to a reversible
cause.
The clinical attributes ADAS, MOCA, MMSE, CDR, FAQ and RAVLT co-occurred fre-
quently. Interestingly, the question number 13 (number of targets hit) from the ADAS test
occurred very frequently in redescription queries. In this task, the participants are required to
cross-out specific digits from a long list of digits. High frequency co-occurrences and corre-
sponding correlations for all aforementioned attributes can be seen in Table 8.
There was also a strong association of the ADAS, CDR and MOCA clinical attributes with
FDG-PET and SPARE_AD, the volume of the entorhinal cortex and the hippocampus, and
other biological attributes (see Table 9). Correlations between these attributes were statistically
significant. One of the most interesting associations is that between CDRSB and PAPP-A
which is used in screening tests for Down syndrome. CDRSB and PAPP-A negatively corre-
lated (−0.15) and the correlation was statistically significant at the significance level of 0.01.
Table 8. The top five associations between pairs of clinical attributes as measured by their co-occurrence in redescription queries. Attribute correla-
tions for a redescription set Ri are computed on dataset Di. P denotes the Pearson correlation coefficient and S denotes the Spearman’s correlation coeffi-
cient. Ru ¼ R1 [R2 [R3. Correlations for attribute pairs from the redescription set Ru are computed on the largest dataset containing both attributes.
Pairwise associations and correlations between clinical attributes
RS Attribute pair Co-occurrence Test Correlation p-value
R1 ADAS13, RAVLT 52 S −0.8 <2.2  10−16
ADAS13, Q13SCORE 49 S 0.5 <2.2  10−16
ADAS13, CDMEMORY 48 S 0.5 <2.2  10−16
ADAS13, FAQ 45 S 0.67 <2.2  10−16
RAVLT, CDMEMORY 43 S −0.63 <2.2  10−16
R2 MOCA, ADAS13 60 S −0.72 <2.2  10−16
MOCA, EcogPtPlan 30 S −0.28 <2.2  10−16
MOCA, CDMEMORY 27 S −0.58 <2.2  10−16
ADAS13, MMSE 24 S −0.64 <2.2  10−16
ADAS13, CDRSB 23 S 0.66 <2.2  10−16
R3 ADAS13, CDMEMORY 60 S 0.76 <2.2  10−16
MMSE, CDMEMORY 42 S −0.73 <2.2  10−16
ADAS13, CDRSB 34 S 0.76 <2.2  10−16
ADAS13, MMSE 30 S −0.71 <2.2  10−16
FAQ, ADAS13 29 S 0.7 <2.2  10−16
Ru ADAS13, CDMEMORY 122 S 0.5 <2.2  10−16
ADAS13, FAQ 82 S 0.67 <2.2  10−16
ADAS13, CDRSB 79 S 0.72 <2.2  10−16
ADAS13, RAVLT 77 S −0.8 <2.2  10−16
ADAS13, MMSE 77 S −0.69 <2.2  10−16
https://doi.org/10.1371/journal.pone.0187364.t008
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Associations with PAPP-A. Motivated by the statistically significant association between
PAPP-A and CDRSB, we used constraint-based redescription mining to create a new rede-
scription set (on dataset D3) by focusing only on redescriptions containing PAPP-A as one of
the attributes in the redescription queries (corresponding redescription set is presented in sup-
plementary document S16 File). The associations from this redescription set, containing 100
redescriptions, are presented in Table 10. Support sets of all constructed redescriptions con-
tained both male and female subjects with diagnosis LMCI and AD.
The associations presented in Table 10 show that PAPP-A occurs frequently in redescrip-
tion queries together with the clinical tests CDMEMORY, CDRSB, MMSE and ADAS13. Cor-
relations between PAPP-A and all these attributes were statistically significant at the
significance level of 0.01. Interestingly, SPARE_AD and PAPP-A occurred in every redescrip-
tion from the redescription set obtained with constraint-based redescription mining. As noted
earlier, the correlation between these two attributes was not statistically significant when mea-
sured for all subjects in the dataset. However, the correlation (Spearman’s ρ = −0.096) was sta-
tistically significant (with p = 0.026) when measured for subjects with AD and LMCI at the
significance level of 0.05. The fact that every redescription in the set obtained with constraint-
based redescription mining described exclusively subjects with AD and LMCI possibly
explains the high frequency of association between those attributes and necessitates further
exploration of the role of PAPP-A in AD and LMCI. Additionally, we found an interesting
association between PAPP-A and two other biological attributes: the volume of the entorhinal
Table 9. The top five associations between pairs of attributes consisting of a clinical and a biological attribute. The association is measured as their
co-occurrence in redescription queries. Attribute correlations for a redescription set Ri are computed on dataset Di. P denotes the Pearson correlation coeffi-
cient and S denotes the Spearman’s correlation coefficient. Ru ¼ R1 [R2 [R3. Correlations for attribute pairs from the redescription set Ru are computed on
the largest dataset containing both attributes.
Pairwise associations and correlations between a biological and a clinical attribute
RS Attribute pair Co-occurrence Test Correlation p-value
R1 ADAS13, FDG 197 S −0.58 <2.2  10−16
ADAS13, Entorhinal 99 S −0.49 <2.2  10−16
ADAS13, Hippocampus 96 S −0.54 <2.2  10−16
ADAS11, FDG 79 S −0.55 <2.2  10−16
CDMEMORY, FDG 69 S −0.49 <2.2  10−16
R2 ADAS13, FDG 142 S −0.56 <2.2  10−16
MOCA, FDG 124 S 0.49 <2.2  10−16
ADAS13, Entorhinal 52 S −0.38 <2.2  10−16
MOCA, Hippocampus 44 S 0.45 <2.2  10−16
RAVLT, FDG 42 S 0.48 <2.2  10−16
R3 ADAS13, SPARE_AD 131 S 0.68 <2.2  10−16
CDMEMORY, SPARE_AD 110 S 0.72 <2.2  10−16
CDRSB, SPARE_AD 58 S 0.7 <2.2  10−16
MMSE, SPARE_AD 51 S −0.62 <2.2  10−16
CDRSB, PAPP-A 43 S −0.15 0.0002
Ru ADAS13, FDG 339 S −0.58 <2.2  10−16
ADAS13, Entorhinal 171 S −0.49 <2.2  10−16
ADAS13, Hippocampus 136 S −0.54 <2.2  10−16
ADAS13, SPARE_AD 131 S 0.68 <2.2  10−16
MOCA, FDG 124 S 0.49 <2.2  10−16
https://doi.org/10.1371/journal.pone.0187364.t009
Relating clinical and biological characteristics of cognitively impaired and AD patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0187364 October 31, 2017 25 / 35
cortex and the volume of the fusiform gyrus (Fusiform). Correlations between PAPP-A and
these biological attributes were statistically significant at the significance level of 0.05.
Discussion
The redescription mining approach to segmenting high-dimensional datasets offers several
advantages over classical clustering, subgroup discovery and association mining, such as the
capability to generate relevant equivalence associations among combinations of attributes. We
performed redescription mining experiments on three different datasets, created by extracting
different sets of attributes from the ADNI database, and measured the redescription accuracy
and the level of homogeneity (in terms of level of cognitive impairment) of the subjects
described by each redescription. Basically, the main aim of our study has been to differentiate
between cognitively normal subjects and those with some level of cognitive impairment, using
clinical and biological attributes potentially related to AD. Our experiments over the con-
structed datasets were deliberately split into different support ranges in terms of subjects
described with redescriptions to allow extracting general and specific, relevant AD-related
information.
In this study, we found a number of surprisingly large and homogeneous groups and many
smaller, more specific subgroups of subjects that are described with informative redescriptions,
in a large extent confirming findings of previous works, corroborating some previously debat-
able findings or providing additional information about various attributes. After obtaining
interesting associations with PAPP-A, we used the introduced extensions to the CLUS-RM
algorithm to perform constraint-based redescription mining, allowing us to further explore
associations of various attributes with PAPP-A. CLUS-RM is extended to perform fully auto-
mated constraint-based redescription mining on data containing either numerical, categorical
attributes or missing values. In addition, it is equipped with soft and suggested CBRM capabil-
ity, introduced in this work.
The clinical attribute CDR (CDMEMORY, CDGLOBAL and CDR-SB) was shown to be a
very good attribute for differentiating CN subjects and subjects with some level of cognitive
impairment. The gene variant APOE ε4 was associated with subjects with high level of cogni-
tive impairment (LMCI and AD), whereas the biological attribute SPARE_AD was highly cor-
related with the subject’s diagnosis.
Table 10. The top four associations of PAPP-A with other attributes based on attribute pair occurrences in redescription queries obtained by
using constraint-based redescription mining on dataset D3. S denotes Spearman’s correlation coefficient. The produced redescription set contains 100
different redescriptions.
Associations of PAPP-A with biological attributes
Attribute pair Co-occurrence Test Correlation p-value
SPARE_AD, PAPP-A 100 S −0.05 0.1
Fusiform, PAPP-A 21 S 0.11 0.01
Entorhinal, PAPP-A 20 S 0.08 0.039
Hippocampus, PAPP-A 13 S 0.01 0.4
Associations of PAPP-A with clinical attributes
Attribute pair Co-occurrence Test Correlation p-value
CDMEMORY, PAPP-A 85 S −0.11 0.0034
CDRSB, PAPP-A 51 S −0.15 0.00019
MMSE, PAPP-A 49 S 0.13 0.00088
ADAS13, PAPP-A 42 S −0.11 0.0056
https://doi.org/10.1371/journal.pone.0187364.t010
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Additionally, high association of ADAS, CDR, and MOCA clinical attributes with
FDG-PET, SPARE_AD, and the volume of the entorhinal cortex and hippocampus were
shown. When describing homogeneous groups of subjects with high level of cognitive
impairment (LMCI and AD), the decrease of testosterone plasma levels, CNTF plasma levels
and increase of BNP plasma levels were observed. Likewise, changes in other biological attri-
butes previously reported as being altered in AD, such as increase in levels of serum apolipo-
protein B, pancreatic polypeptide, plasma insulin and Fas (CD95) were found.
Finally, probably the most important finding of this study was the detection of altered levels
of those biological attributes, for subjects with cognitive impairment, that could have potential
as therapeutic targets in AD, namely decreased leptin and increased angiopoietin-2 plasma lev-
els. Decreasing leptin levels have been suggested to alleviate AD-related cellular changes in
rabbit organotypic slices [87] and in human neuroblastoma cell culture [88, 89], suggesting
that lowered leptin levels detected in AD subjects can be a possible target for developing sup-
plementation therapies for reducing the progression of AD. The finding of increased angio-
poietin-2 plasma levels in AD patients is in accordance with the study of Thirumangalakudi
et al. [66], who showed that angiopoietin-2 is expressed by AD, but not control-derived micro-
vessels, supporting the idea of targeting the angiogenic changes in the microcirculation of the
AD brain as a potential therapeutic approach in AD [67]. Altogether, analysing redescriptions
from all three different datasets allowed finding many different associations. Some of these
associations, such as SPARE_AD and PAPP-A are novel and require more in depth analysis
with the supervision of domain experts. The correlation between SPARE_AD and PAPP-A
was not statistically significant when computed for all subjects contained in the dataset R3, but
it was statistically significant when computed only for subjects with AD and LMCI at the sig-
nificance level of 0.05. PAPP-A showed significant correlation with the volume of the Fusiform
gyrus and the volume of the Entorhinal cortex—both already known as being associated with
AD [90, 91]. Further, PAPP-A had statistically significant correlation to the most widely used
clinical cognitive tests: ADAS, Mini-Mental State Examination and Clinical Dementia Rating
Sum of Boxes.
It has been shown [92] by measuring the reference intervals of PAPP-A (in 52 healthy
males and 74 healthy, non-pregnant women) that the reference intervals are <22.9 ng/mL for
men and<33.6 ng/mL for non-pregnant women. PAPP-A levels of smokers were lower than
that of non-smokers and there is a positive correlation between serum PAPP-A levels and sub-
jects’ age. The measured median value of PAPP-A in males 6.85 with the range [undetectable,
24, 40] ng/mL were significantly higher than the median of female subjects 3.4 with the mea-
sured range [undetectable, 36, 7] ng/ml. For both males and females, non-smokers had higher
levels of PAPP-A than smokers. For males, the difference was statistically significant and for
females, it was not. PAPP-A levels in pre-menopause women were lower than in the post-men-
opause women, however the difference was not statistically significant. In male subjects, the
study found a significant correlation between subjects’ age and the level of PAPP-A, however
in female subjects this correlation was not statistically significant.
Our search (PubMed search on 3 March 2016.) by using the keywords pappalysin-1/Preg-
nancy-associated plasma protein-A (PAPP-A) and Alzheimer’s disease revealed only one publi-
cation [93] that associates PAPP-A with depressive symptoms.
Results by Llano et al. [78] show that PAPP-A is among the most significant descriptors in
plasma proteomic data for distinguishing between CN, MCI and AD patients by different
supervised machine learning algorithms. We discovered associations between PAPP-A and
cognitive status (LMCI, AD). These results demonstrate the importance of further study of
PAPP-A as potential marker for early detection of AD.
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Distribution analysis of PAPP-A values based on our data and those of Llano et al. [78]
show that PAPP-A levels are increased in MCI and LMCI patients but are significantly
decreased in subjects diagnosed with AD. Decrease in PAPP-A levels from LMCI to AD
patients on our data is more pronounced in female than in male patients. The possible link
between PAPP-A and AD related genes (ABCA1,ABCG1) discovered in Hu et al. [94] is
explained by Tang et al. [95]. This publication discusses the role of PAPP-A in pathogenesis of
atherosclerosis through its inhibition of liver X receptors α (LXRα) through the insulin-like
growth factor (IGF)-I-mediated signalling pathway, and negative regulation of expression of
ABCA1 and ABCG1 genes—all significantly associated with AD [94]. Although LXR are best
known as the key regulators of cholesterol metabolism and transport, LXR signaling has also
been shown to have significant anti-inflammatory properties [96]. Various studies surveyed in
sˇtefulj et al. [96] implicate LXR in the pathogenesis, modulation, and therapy of AD.
Further potential association between PAPP-A and AD can be seen through study of
patients suffering form type-2 diabetes. It has been shown [97] that patients suffering from
type-2 diabetes also have significantly increased level of PAPP-A. Akter et al. [98] showed the
potentially shared pathology of type-2 diabetes and AD, where some research (e.g. [99]),
shows high influence of type-2 diabetes on the potential development of AD. Also, one study
performed on mice [100] suggested that changes in the brain during AD can potentially cause
diabetes.
Conclusion
The association of PAPP-A (previously known as pappalysin-1) with cognitive status is proba-
bly the most intriguing and novel finding of this study, as it has been scarcely investigated in
this context.
PAPP-A was detected as a significant attribute in differentiating between CN, MCI and AD
subjects [78] through use of different supervised machine learning algorithms. It has also been
shown that it is significant in predicting the progression from MCI to AD, though none of the
used subsets of attributes provided adequate predictions of progression between these two
classes. High association of PAPP-A with depressive symptoms has already been demonstrated
[93] by using the ensemble machine learning algorithm of Random Forests.
In our work, we detected important correlation between the attribute PAPP-A and the cog-
nitive test CDRSB. By applying the newly developed constraint-based extensions of the
CLUS-RM algorithm, we detected a larger number of attributes with statistically significant
correlation with PAPP-A. In addition to CDRSB, we observed more clinical tests, such as
MMSE and ADAS13, with statistically significant correlations with PAPP-A. Interesting and
significant correlations were also observed with the biological attributes: volume of the Fusi-
form gyrus and volume of the Entorhinal cortex both known as being associated with AD [90,
91] with the volume of Entorhinal cortex being significantly reduced even in the mild case of
AD [91].
The high importance of our finding lies in the fact that PAPP-A is a metalloproteinase,
already known to cleave insulin-like growth factor (IGF) binding proteins (IGFBPs). Perhaps
even more importantly, since it also shares similar substrates with the A Disintegrin and
Metalloproteinase (ADAM) family of enzymes (the main group of enzymes that act as α-secre-
tase to physiologically cleave the amyloid precursor protein (APP) in the so-called non-amyloi-
dogenic pathway [101]), it could be directly involved in the metabolism of the amyloid
precursor protein (APP) in the very early stages of AD. Based on the above, the role of
PAPP-A in AD should be investigated in greater details.
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